The PURE EP™ System sets a new standard in electrophysiology by providing essential intracardiac signals with high clinical value in all types of cardiac ablations.
Now combining the best-in-class intracardiac signal acquisition technology with the new PURE EP™ Software Version 4 designed around 4 key procedural steps.
More than 940 patient cases have been conducted using the PURE EP™ System by 52 physicians in nine clinical sites to date.
Abstracts are due to be presented by physician users and research investigators from two leading institutions. The annual Heart Rhythm 2021 convention takes place on July 28-31, 2021, at the Boston Convention and Exhibition Center in Boston, MA. The Company will be exhibiting at booth 849.
Press Release
Company’s conference program to include physician presentations and new technology demonstrations for its proprietary signal processing system for arrhythmia care. The Heart Rhythm 2021 convention is due to take place on July 28-31, 2021 at the Boston Convention and Exhibition Center in Boston, MA.
Press Release
Physicians at Mayo Clinic’s campus in Phoenix, Arizona have started using the Company’s PURE EP(tm) System in the patient cases treating cardiac arrhythmias. The 30-day clinical evaluation of the PURE EP(tm) System is being conducted by the cardiac electrophysiologists Win-Kuang Shen, M.D., Hichan El Masry, M.D., Arturo Valverde, M.D. and Luis Scott, M.D.
Press Release
51 patients undergoing elective cardiac ablation treatments were enrolled in the trial at Mayo Clinic, Massachusetts General Hospital, and St. David’s Medical Center. The trial is designed to demonstrate the quality and clinical value of the PURE EPTM signals when compared to conventional sources of cardiac signals.
Press Release
Bioelectronic medicine is a new, rapidly growing field of healthcare that explores how targeted electrical signals in the body can help to diagnose and treat a wide range of diseases, from diabetes to depression.
BioSig aims to play a vital role in the field of bioelectronic medicine, based on our unique enabling technology and core competency in signal processing. Our initial focus is on heart disease and the fast-growing electrophysiology device market.
By improving signal clarity, BioSig’s PURE EP™ System has the potential to deliver valuable advances in electrophysiology procedures. We recently conducted first clinical cases at the Texas Cardiac Arrhythmia Institute under the leadership of Andrea Natale, M.D., F.A.C.C., F.H.R.S., F.E.S.C., Executive Medical Director, Texas Cardiac Arrhythmia Institute at St. David’s Medical Center. According to Dr. Natale, early results suggested improved cardiac signal detection and fidelity - click here to read the announcement.
How Does Pure EP™ Work?BioSig is a NASDAQ-traded company with a clear path to commercialization and growth, proven credentials for success, and a world-class leadership team. Check out our Investor Resources for financial and governance information, stock performance, SEC filings, and other materials.
